Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants

Phase 1/2 Recruiting 68 enrolled N-Fold, LLC CBCC Global Research · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)

Timeline

Start: 2025-12-16
Primary completion: 2028-11
Completion: 2028-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENP-501	Unknown	2000 ug	Other

Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants

Summary

Timeline

Drugs

Indications